{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:55:06Z","timestamp":1757573706540,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) poses a\u00a0unique challenge due to its predilection for developing on compromised livers, often limiting surgical options. Stereotactic body radiotherapy (SBRT) has emerged as a\u00a0promising local treatment modality for HCC. This study aims to assess the effectiveness of SBRT in HCC patients not suitable for surgery, focusing on local control, optimal radiation dosing, and prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective analysis, 52 HCC patients treated with SBRT were examined. The study assessed local control, progression-free survival (PFS), and overall survival (OS) while conducting dosimetric analyses. The relationship between mean liver dose and Child\u2013Pugh score (CPS) progression was also explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SBRT demonstrated 93.4% freedom from local progression (FFLP) at 12\u00a0months. Notably, a\u00a0near minimum dose (D98%) below 61\u202fGy as an equivalent dose in 2\u2011Gy fractions with \u03b1\/\u03b2 10\u202fGy (EQD2<jats:sub>\u03b1\/\u03b210<\/jats:sub>) was associated with reduced FFLP (<jats:italic>p<\/jats:italic>-value 0.034). Logistic regression analysis revealed a\u00a0dose\u2013response relationship for FFLP and D98% with 95% and 98% probability of FFLP at a\u00a0dose of 56.9 and 73.1\u202fGy, respectively. The study observed OS rates of 63.7% at 1\u00a0year and 34.3% at 3\u00a0years. Patients with portal vein tumor thrombus (PVTT) and larger tumors (\u2265\u202f37\u202fcm<jats:sup>3<\/jats:sup>) experienced decreased PFS and OS. Multivariate analysis identified PVTT, larger tumor volume, and performance status as independent predictors of reduced OS. Notably, classical radiation-induced disease (cRILD) was absent, but nonclassical (nc) RILD occurred in 7.7% of patients. Regression analysis linked a\u00a0mean EQD2<jats:sub>\u03b1\/\u03b23\u20138<\/jats:sub> dose to the liver (12.8\u201312.6) with a\u00a010% likelihood of ncRILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SBRT offers a\u00a0compelling option for achieving high local control and promising survival outcomes in HCC. The study supports a\u00a0radiation dose range of 61\u201373.1\u202fGy, coupled with a\u00a0mean liver dose under 12.6\u201312.8\u202fGy as EQD2, to achieve favorable FFLP rates, with acceptable toxicity rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-024-02235-5","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:01:49Z","timestamp":1714496509000},"page":"715-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-1996","authenticated-orcid":false,"given":"Ahmed Allam","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Luise","family":"Berres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Bruners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven Arke","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Wiltberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Barabasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Eble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"3","key":"2235_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Laversanne\u00a0M, Soerjomataram\u00a0I, Jemal\u00a0A, Bray\u00a0F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2235_CR2","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag\u00a0HB, Rudolph\u00a0KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557\u20132576","journal-title":"Gastroenterology"},{"issue":"1","key":"2235_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle\u00a0PR, Forner\u00a0A, Llovet\u00a0JM, Mazzaferro\u00a0V, Piscaglia\u00a0F, Raoul\u00a0JL, Schirmacher\u00a0P, Vilgrain\u00a0V (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J\u00a0Hepatol 69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"issue":"4","key":"2235_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/hepr.13612","volume":"51","author":"M Kudo","year":"2021","unstructured":"Kudo\u00a0M, Izumi\u00a0N, Kokudo\u00a0N, Sakamoto\u00a0M, Shiina\u00a0S, Takayama\u00a0T, Tateishi\u00a0R, Nakashima\u00a0O, Murakami\u00a0T, Matsuyama\u00a0Y et\u00a0al (2021) Report of the 21st\u00a0nationwide follow-up survey of primary liver cancer in Japan (2010\u20132011). Hepatol Res 51(4):355\u2013405","journal-title":"Hepatol Res"},{"issue":"5","key":"2235_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","volume":"196","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M, Baus\u00a0WW, Blanck\u00a0O, Combs\u00a0SE, Debus\u00a0J, Engenhart-Cabillic\u00a0R, Gauer\u00a0T, Grosu\u00a0AL, Schmitt\u00a0D, Tanadini-Lang\u00a0S et\u00a0al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol 196(5):417\u2013420. https:\/\/doi.org\/10.1007\/s00066-020-01603-1","journal-title":"Strahlenther Onkol"},{"issue":"10185","key":"2235_CR6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S, Gaede\u00a0S, Louie\u00a0AV, Haasbeek\u00a0C, Mulroy\u00a0L, Lock\u00a0M, Rodrigues\u00a0GB, Yaremko\u00a0BP et\u00a0al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a\u00a0randomised, phase\u00a02, open-label trial. Lancet 393(10185):2051\u20132058. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"issue":"6","key":"2235_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00066-017-1099-8","volume":"193","author":"E Gkika","year":"2017","unstructured":"Gkika\u00a0E, Adebahr\u00a0S, Kirste\u00a0S, Schimek-Jasch\u00a0T, Wiehle\u00a0R, Claus\u00a0R, Wittel\u00a0U, Nestle\u00a0U, Baltas\u00a0D, Grosu\u00a0AL et\u00a0al (2017) Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer. Strahlenther Onkol 193(6):433\u2013443. https:\/\/doi.org\/10.1007\/s00066-017-1099-8","journal-title":"Strahlenther Onkol"},{"issue":"13","key":"2235_CR8","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold\u00a0A, Massey\u00a0CA, Kim\u00a0JJ, Brierley\u00a0J, Cho\u00a0C, Wong\u00a0RKS, Dinniwell\u00a0RE, Kassam\u00a0Z, Ringash\u00a0J, Cummings\u00a0B et\u00a0al (2013) Sequential phase\u00a0I and\u00a0II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J\u00a0Clin Oncol 31(13):1631\u20131639","journal-title":"J Clin Oncol"},{"issue":"6","key":"2235_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","volume":"16","author":"JY Chang","year":"2015","unstructured":"Chang\u00a0JY, Senan\u00a0S, Paul\u00a0MA, Mehran\u00a0RJ, Louie\u00a0AV, Balter\u00a0P, Groen\u00a0HJM, McRae\u00a0SE, Widder\u00a0J, Feng\u00a0L et\u00a0al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage\u00a0I non-small-cell lung cancer: a\u00a0pooled analysis of two randomised trials. Lancet Oncol 16(6):630\u2013637","journal-title":"Lancet Oncol"},{"key":"2235_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02180-9","author":"AA Mohamed","year":"2024","unstructured":"Mohamed\u00a0AA, Goncalves\u00a0M, Singh\u00a0BP, Tometten\u00a0M, Rashad\u00a0A, H\u00f6lzle\u00a0F, Hackenberg\u00a0S, Eble\u00a0M (2024) Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a\u00a0single-center experience. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-023-02180-9","journal-title":"Strahlenther Onkol"},{"key":"2235_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30591","author":"K Hara","year":"2019","unstructured":"Hara\u00a0K, Takeda\u00a0A, Tsurugai\u00a0Y, Saigusa\u00a0Y, Sanuki\u00a0N, Eriguchi\u00a0T, Maeda\u00a0S, Tanaka\u00a0K, Numata\u00a0K (2019) Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a\u00a0propensity score analysis. Hepatology. https:\/\/doi.org\/10.1002\/hep.30591","journal-title":"Hepatology"},{"issue":"4","key":"2235_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/hepr.12359","volume":"45","author":"T Kimura","year":"2015","unstructured":"Kimura\u00a0T, Aikata\u00a0H, Takahashi\u00a0S, Takahashi\u00a0I, Nishibuchi\u00a0I, Doi\u00a0Y, Kenjo\u00a0M, Murakami\u00a0Y, Honda\u00a0Y, Kakizawa\u00a0H et\u00a0al (2015) Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 45(4):378\u2013386","journal-title":"Hepatol Res"},{"issue":"3","key":"2235_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00066-018-1391-2","volume":"195","author":"CL Chiang","year":"2019","unstructured":"Chiang\u00a0CL, Chan\u00a0MKH, Yeung\u00a0CSY, Ho\u00a0CHM, Lee\u00a0FAS, Lee\u00a0VWY, Wong\u00a0FCS, Blanck\u00a0O (2019) Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage\u00a0B\u2013C hepatocellular carcinoma. Strahlenther Onkol 195(3):254\u2013264. https:\/\/doi.org\/10.1007\/s00066-018-1391-2","journal-title":"Strahlenther Onkol"},{"key":"2235_CR14","doi-asserted-by":"crossref","unstructured":"Jacob R, Turley F, Redden DT, Saddekni S, Aal AKA, Keene K, Yang E, Zarzour J, Bolus D, Smith JK et\u00a0al (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of \u2265\u202f3\u202fcm. https:\/\/www.hpbonline.org\/article\/S1365-182X(15)31172-2\/pdf. Accessed 27 July 2019","DOI":"10.1111\/hpb.12331"},{"issue":"11","key":"2235_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1097\/MEG.0000000000002442","volume":"34","author":"HS Shin","year":"2022","unstructured":"Shin\u00a0HS, Hwan Lee\u00a0S, Jun\u00a0BG, Kim\u00a0HS, Kang\u00a0SH, Park\u00a0JY, Choi\u00a0SI, Cheon\u00a0GJ, Kim\u00a0YD, Yoo\u00a0JJ et\u00a0al (2022) Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 34(11):1187\u20131194","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"2235_CR16","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/hep.31992","volume":"74","author":"TCL Wong","year":"2021","unstructured":"Wong\u00a0TCL, Lee\u00a0VHF, Law\u00a0ALY, Pang\u00a0HH, Lam\u00a0KO, Lau\u00a0V, Cui\u00a0TY, Fong\u00a0ASY, Lee\u00a0SWM, Wong\u00a0ECY et\u00a0al (2021) Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology 74(5):2580","journal-title":"Hepatology"},{"key":"2235_CR17","doi-asserted-by":"publisher","unstructured":"Lencioni R, Llovet JM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. https:\/\/doi.org\/10.1055\/s-0030-1247132. Accessed 4 Jan 2020","DOI":"10.1055\/s-0030-1247132"},{"issue":"1","key":"2235_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jnci.2015.08.001","volume":"28","author":"R Benson","year":"2016","unstructured":"Benson\u00a0R, Madan\u00a0R, Kilambi\u00a0R, Chander\u00a0S (2016) Radiation induced liver disease: a\u00a0clinical update. J\u00a0Egypt Natl Canc Inst 28(1):7\u201311","journal-title":"J Egypt Natl Canc Inst"},{"issue":"3","key":"2235_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.prro.2017.10.013","volume":"8","author":"TR Chapman","year":"2018","unstructured":"Chapman\u00a0TR, Bowen\u00a0SR, Schaub\u00a0SK, Yeung\u00a0RH, Kwan\u00a0SW, Park\u00a0JO, Yu\u00a0L, Harris\u00a0WP, Johnson\u00a0GE, Liou\u00a0IW et\u00a0al (2018) Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol 8(3):157\u2013166","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2235_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1748-717X-8-61","volume":"8","author":"SH Son","year":"2013","unstructured":"Son\u00a0SH, Jang\u00a0HS, Lee\u00a0H, Choi\u00a0BO, Kang\u00a0YN, Jang\u00a0JW, Yoon\u00a0SK, Kay\u00a0CS (2013) Determination of the \u03b1\/\u03b2 ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat Oncol 8(1):61","journal-title":"Radiat Oncol"},{"issue":"3","key":"2235_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0360-3016(91)90069-G","volume":"20","author":"TS Lawremce","year":"1991","unstructured":"Lawremce\u00a0TS, Dworzanin\u00a0LM, Walker-Andrews\u00a0SC, Andrews\u00a0JC, Ten Haken\u00a0RK, Wollmer\u00a0IS, Lichter\u00a0AS, Ensminger\u00a0WD (1991) Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 20(3):555\u2013561","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2235_CR22","doi-asserted-by":"crossref","unstructured":"Durand-Labrunie J, Baumann A (2020) Curative irradiation treatment of hepatocellular carcinoma: a\u00a0multicenter phase\u00a02\u00a0trial. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0360301619345122. Accessed 3 Oct 2023","DOI":"10.1016\/j.ijrobp.2019.12.004"},{"issue":"2","key":"2235_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cncr.32502","volume":"126","author":"JW Il","year":"2020","unstructured":"Il\u00a0JW, Bae\u00a0SH, Kim\u00a0MS, Han\u00a0CJ, Park\u00a0SC, Kim\u00a0SB, Cho\u00a0EH, Choi\u00a0CW, Kim\u00a0KS, Hwang\u00a0S et\u00a0al (2020) A\u00a0phase\u00a02 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. Cancer 126(2):363\u2013372","journal-title":"Cancer"},{"issue":"4","key":"2235_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/hepr.13595","volume":"51","author":"T Kimura","year":"2021","unstructured":"Kimura\u00a0T, Takeda\u00a0A, Sanuki\u00a0N, Ariyoshi\u00a0K, Yamaguchi\u00a0T, Imagumbai\u00a0T, Katoh\u00a0N, Eriguchi\u00a0T, Oku\u00a0Y, Ozawa\u00a0S et\u00a0al (2021) Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatol Res 51(4):461\u2013471","journal-title":"Hepatol Res"},{"issue":"5","key":"2235_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","volume":"34","author":"DR Wahl","year":"2016","unstructured":"Wahl\u00a0DR, Stenmark\u00a0MH, Tao\u00a0Y, Pollom\u00a0EL, Caoili\u00a0EM, Lawrence TS, Schipper\u00a0MJ, Feng\u00a0M (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J\u00a0Clin Oncol 34(5):452\u2013459. https:\/\/doi.org\/10.1200\/JCO.2015.61.4925","journal-title":"J Clin Oncol"},{"issue":"1","key":"2235_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","volume":"73","author":"N Kim","year":"2020","unstructured":"Kim\u00a0N, Cheng\u00a0J, Jung\u00a0I, Liang\u00a0JD, Shih\u00a0YL, Huang\u00a0WY, Kimura\u00a0T, Lee\u00a0VHF, Zeng\u00a0ZC, Zhenggan\u00a0R et\u00a0al (2020) tereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J\u00a0Hepatol 73(1):121\u2013129","journal-title":"J Hepatol"},{"issue":"1","key":"2235_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","volume":"100","author":"E Sapir","year":"2018","unstructured":"Sapir\u00a0E, Tao\u00a0Y, Schipper\u00a0MJ, Bazzi\u00a0L, Novelli\u00a0PM, Devlin\u00a0P, Owen\u00a0D, Cuneo\u00a0KC, Lawrence\u00a0TS, Parikh\u00a0ND et\u00a0al (2018) Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 100(1):122\u2013130","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"2235_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","volume":"117","author":"A M\u00e9ndez Romero","year":"2023","unstructured":"M\u00e9ndez Romero\u00a0A, van der Holt\u00a0B, Willemssen\u00a0FEJA, de Man\u00a0RA, Heijmen\u00a0BJM, Habraken\u00a0S, Westerveld\u00a0H, van Delden\u00a0OM, Kl\u00fcmpen\u00a0HJ, Tjwa\u00a0ETTL et\u00a0al (2023) Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a\u00a0multicenter, randomized, phase\u00a02 trial (the TRENDY trial). Int J Radiat Oncol Biol Phys 117(1):45\u201352","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2235_CR29","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.3390\/curroncol29110692","volume":"29","author":"T Comito","year":"2022","unstructured":"Comito\u00a0T, Loi\u00a0M, Franzese\u00a0C, Clerici\u00a0E, Franceschini\u00a0D, Badalamenti\u00a0M, Teriaca\u00a0MA, Rimassa\u00a0L, Pedicini\u00a0V, Poretti\u00a0D et\u00a0al (2022) Stereotactic radiotherapy after incomplete transarterial (chemo-) embolization (TAE\\TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a\u00a0phase\u00a0III trial (NCT02323360). Curr Oncol 29(11):8802\u20138813","journal-title":"Curr Oncol"},{"key":"2235_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.653141","author":"TB Brunner","year":"2021","unstructured":"Brunner\u00a0TB, Bettinger\u00a0D, Schultheiss\u00a0M, Maruschke\u00a0L, Sturm\u00a0L, Bartl\u00a0N, Koundurdjieva\u00a0I, Kirste\u00a0S, Neeff\u00a0HP, Goetz\u00a0C et\u00a0al (2021) Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical efficacy study). Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.653141","journal-title":"Front Oncol"},{"issue":"1","key":"2235_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","volume":"110","author":"N Ohri","year":"2021","unstructured":"Ohri\u00a0N, Tom\u00e9\u00a0WA, M\u00e9ndez Romero\u00a0A, Miften\u00a0M, Ten Haken\u00a0RK, Dawson\u00a0LA, Grimm\u00a0J, Yorke\u00a0E, Jackson\u00a0A (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188\u2013195","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"2235_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-8-250","volume":"8","author":"WI Jang","year":"2013","unstructured":"Jang\u00a0WI, Kim\u00a0MS, Bae\u00a0SH, Cho\u00a0CK, Yoo\u00a0HJ, Seo\u00a0YS, Kang\u00a0JK, Kim\u00a0SY, Lee\u00a0DH, Han\u00a0CJ et\u00a0al (2013) High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 8(1):1\u201312. https:\/\/doi.org\/10.1186\/1748-717X-8-250","journal-title":"Radiat Oncol"},{"key":"2235_CR33","doi-asserted-by":"crossref","unstructured":"Su TS, Liu QH, Zhu XF, Liang P, Liang SX, Lai L, Zhou Y, Huang Y, Cheng T, Li LQ (2021) Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a\u00a0multicenter study. Radiat Oncol 16(1)","DOI":"10.1186\/s13014-021-01778-6"},{"key":"2235_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02846-8","volume-title":"Analysis of radiation-induced liver disease using the Lyman NTCP model","author":"LA Dawson","year":"2002","unstructured":"Dawson\u00a0LA, Normolle\u00a0D, Balter\u00a0JM, Mcginn\u00a0CJ, Lawrence\u00a0TS, Ten Haken\u00a0RK (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model"},{"issue":"1","key":"2235_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13014-023-02232-5","volume":"18","author":"JX Li","year":"2023","unstructured":"Li\u00a0JX, Zhang\u00a0RJ, Qiu\u00a0MQ, Yan\u00a0LY, He\u00a0ML, Long\u00a0MY, Zhong\u00a0JH, Lu\u00a0HY, Zhou\u00a0HM, Xiang\u00a0B\u2011D et\u00a0al (2023) Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade\u00a0B patients with locally advanced hepatocellular carcinoma. Radiat Oncol 18(1):48","journal-title":"Radiat Oncol"},{"key":"2235_CR36","doi-asserted-by":"crossref","unstructured":"Bae S, Park H, Yoon W et\u00a0al (2019) Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with Child-Pugh classification B in Korea (KROG 16-05). https:\/\/synapse.koreamed.org\/articles\/1153809. Accessed 6 Oct 2023","DOI":"10.4143\/crt.2018.687"},{"issue":"9","key":"2235_CR37","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s00066-023-02065-x","volume":"199","author":"D Sharma","year":"2023","unstructured":"Sharma\u00a0D, Thaper\u00a0D, Kamal\u00a0R, Yadav\u00a0HP (2023) Role of palliative SBRT in barcelona clinic liver cancer-stage\u00a0C hepatocellular carcinoma patients. Strahlenther Onkol 199(9):838\u2013846. https:\/\/doi.org\/10.1007\/s00066-023-02065-x","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"2235_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1200\/JCO.2023.41.4_suppl.489","volume":"41","author":"LA Dawson","year":"2023","unstructured":"Dawson\u00a0LA, Winter\u00a0KA, Knox\u00a0JJ et\u00a0al (2023) NRG\/RTOG 1112: randomized phase\u00a0III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). J\u00a0Clin Oncol 41(4):489. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.489","journal-title":"J Clin Oncol"},{"issue":"1","key":"2235_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","volume":"115","author":"A Juloori","year":"2023","unstructured":"Juloori\u00a0A, Katipally\u00a0RR, Lemons\u00a0JM, Singh\u00a0AK, Iyer\u00a0R, Robbins\u00a0JR, George\u00a0B, Hall\u00a0WA, Pitroda\u00a0SP, Arif\u00a0F et\u00a0al (2023) Phase\u00a01 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 115(1):202\u2013213","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"2235_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00066-018-1385-0","volume":"195","author":"E Gkika","year":"2019","unstructured":"Gkika\u00a0E, Strouthos\u00a0I, Kirste\u00a0S, Adebahr\u00a0S, Schultheiss\u00a0M, Bettinger\u00a0D, Fritsch\u00a0R, Brass\u00a0V, Maruschke\u00a0L, Neeff\u00a0HP et\u00a0al (2019) Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol 195(3):246\u2013253. https:\/\/doi.org\/10.1007\/s00066-018-1385-0","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02235-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T10:03:22Z","timestamp":1721901802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02235-5"}},"subtitle":["A\u00a0retrospective study"],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02235-5","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"10 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.\u00a0Mohamed, M.-L.\u00a0Berres, P.\u00a0Bruners, S.A.\u00a0Lang, C.\u00a0Trautwein, G.\u00a0Wiltberger, A.\u00a0Barabasch and M.\u00a0Eble declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}